In article <6ossu4$ob3$1 at fir.prod.itd.earthlink.net>,
excelife at earthlink.net (Excelife) wrote:
>In some of my posts I have raised questions regarding transforming growth
>factor beta2,(TGF), and it's effects on the longevity of epidermal cells.
>The responses, (save one), I have received have been a deafening silence. No
>one out there seems to know about this research or it's implications. Why
>not you ask! Well it seems that Genzyme Corp. who has this product in phase
>2 clinical trials hasn't published a damn thing about it!
U.S. patents 5,599,788 and 5,624,840, assigned to Advanced Tissue
Sciences Inc. deal with regenerating skin and liver cells with H3
protein induced by TGF beta. I believe clinical trials are underway
for a technique to help diabetics with the foot problems they
experience, and a second set of clinical trials is being readied
for liver patients. The technique involves a nylon mesh scaffold on
which the organ in question is regenerated. It is applicable to many
organs and is conceivably an alternative to transplants in some cases.
>Well it seems that Genzyme Corp. who has this product in phase
>2 clinical trials hasn't published a damn thing about it!
Wouldn't it be unethical to publish about unfinished clinical trials?
Estradiol and Raloxiphene (estrogens) activate TGF beta3 in the estrogen
receptor and likewise phytoestrogens like Quercetin seem to have
this effect. So perhaps there will be some herbal or "dietary supplement"
options, once it the mechanism is understood.
